This document summarizes a presentation on using trichometry and cross-sectional trichometry (CST) to objectively measure hair loss and monitor treatment outcomes. CST allows clinicians to accurately track changes in hair mass index (HMI) over time to determine treatment effectiveness and progression of hair loss. The document provides examples of how CST can answer questions about treatment responses, compare different treatments, and distinguish shedding from permanent hair loss. CST provides a quantitative tool to optimize hair loss management.
THE ART of SKIN & BODY CARE by ASEPTA LABORATOIRES MONACOAsepta Laboratoires
INNOVATIVE & HIGHLY EFFECTIVE TARGETED PROFESSIONAL TREATMENTS for professional & home use - MADE IN MONACO by ASEPTA LABORATOIRES MONACO | The Laboratory Expert in Dermo-Pharmacy and Leader in Foot Care since 1943.
Discover the benefits of ASEPTA world renown brands: AKILEINE, CYCALEINE, ONYKOLEINE, AKILDIA, AKILWINTER, HELIABRINE, HELIXIENCE, HELIASLIM, COUP D'ECLAT, ECRINAL
Androgenetic Alopecia or hereditary hair loss, considered by many as an outward and undesirable sign of premature aging that can be ‘seen from across the room,’ currently affects an estimated 50 Million men and 30 Million women in the U.S. Approximately 40% of men in their 40’s are experiencing hair loss and 50% of men in their 50’s with over a billion dollars spent in the U.S. annually on medical treatments, hair transplants, non-medical ‘cures’ and cover-ups to address the condition.
Hormone replacement therapy (HRT) that includes androgens/testosterone may accelerate the progression of unwanted androgenetic alopecia, especially in those patients whose hair follicles are highly androgen sensitive.
OBJECTIVE: Patients who undergo testosterone replacement may be at risk for hair loss related side effects. It is our goal to present an overview of the mechanisms of Androgenetic Alopecia, new diagnostic and monitoring methods, prevention/treatments options and management stratagems specifically for patients who are undergoing an Hormone replacement therapy regimen that includes testosterone.
MATERIALS/METHODS:
Chief Complaint & Goals
Medical History
Family history
Medical Conditions
Medications
Surgical History
Hair/Scalp Care
Lab Testing / Measurements
Genetic Testing
Cross Sectional Bundle Trichometry Measurements with Hair Check(TM)
Photography
Standardized Global Photos
Scalp Microscopic Photos
Treatment Plan
Recommended Tracking & Follow-Up Schedule
DISCUSSION
Identifying patients at risk for hereditary hair loss as well as being able to offer guidance and treatment options holds significant benefit for the Age Management (Anti-Aging) Physician and their Hormone Replacement patients because it:
1) enhances the risk/benefit discussion with the testosterone patient.
2) Identifies and addresses a possible side-effect and potential barrier to HRT compliance.
3) Adds a beneficial service to the Age Management Physician’s repertoire that may enhance patient retention and compliance.
4) Successful hair loss management adds a psychological boost to a Androgen Replacement patient’s outlook.
References:
THE ART of SKIN & BODY CARE by ASEPTA LABORATOIRES MONACOAsepta Laboratoires
INNOVATIVE & HIGHLY EFFECTIVE TARGETED PROFESSIONAL TREATMENTS for professional & home use - MADE IN MONACO by ASEPTA LABORATOIRES MONACO | The Laboratory Expert in Dermo-Pharmacy and Leader in Foot Care since 1943.
Discover the benefits of ASEPTA world renown brands: AKILEINE, CYCALEINE, ONYKOLEINE, AKILDIA, AKILWINTER, HELIABRINE, HELIXIENCE, HELIASLIM, COUP D'ECLAT, ECRINAL
Androgenetic Alopecia or hereditary hair loss, considered by many as an outward and undesirable sign of premature aging that can be ‘seen from across the room,’ currently affects an estimated 50 Million men and 30 Million women in the U.S. Approximately 40% of men in their 40’s are experiencing hair loss and 50% of men in their 50’s with over a billion dollars spent in the U.S. annually on medical treatments, hair transplants, non-medical ‘cures’ and cover-ups to address the condition.
Hormone replacement therapy (HRT) that includes androgens/testosterone may accelerate the progression of unwanted androgenetic alopecia, especially in those patients whose hair follicles are highly androgen sensitive.
OBJECTIVE: Patients who undergo testosterone replacement may be at risk for hair loss related side effects. It is our goal to present an overview of the mechanisms of Androgenetic Alopecia, new diagnostic and monitoring methods, prevention/treatments options and management stratagems specifically for patients who are undergoing an Hormone replacement therapy regimen that includes testosterone.
MATERIALS/METHODS:
Chief Complaint & Goals
Medical History
Family history
Medical Conditions
Medications
Surgical History
Hair/Scalp Care
Lab Testing / Measurements
Genetic Testing
Cross Sectional Bundle Trichometry Measurements with Hair Check(TM)
Photography
Standardized Global Photos
Scalp Microscopic Photos
Treatment Plan
Recommended Tracking & Follow-Up Schedule
DISCUSSION
Identifying patients at risk for hereditary hair loss as well as being able to offer guidance and treatment options holds significant benefit for the Age Management (Anti-Aging) Physician and their Hormone Replacement patients because it:
1) enhances the risk/benefit discussion with the testosterone patient.
2) Identifies and addresses a possible side-effect and potential barrier to HRT compliance.
3) Adds a beneficial service to the Age Management Physician’s repertoire that may enhance patient retention and compliance.
4) Successful hair loss management adds a psychological boost to a Androgen Replacement patient’s outlook.
References:
For many, hair loss can be a devastating psychological condition. Unfortunately, dermatologists and primary doctors often fall short when it comes to the state-of-the-art diagnosis and treatment. It's up to hair restoration physicians and integrative practices to take the lead in the medical management of hair loss. Helping patients maintain, enhance and restore their own living and growing hair is a rewarding field to be in. Mismanaging patients expectations or therapies will certainly lead to disappointment. In this webinar, learn an overview of how we diagnose, measure, treat and track hair loss patients on various effective medical regimens. We often prescribe finasteride and FinPlus compounded finasteride, Formula82M minoxidil, LaserCap and in-office laser therapy, PRP with ECM BioD ACell, nutraceuticals and FUE NeoGraft hair transplantation. See some before and afters from various monotherapy patients. HairCheck cross sectional hair bundle trichometry is the key to keeping patients compliant. Thank you to LaserCap
Additional training is available from Dr. Alan J Bauman so visit http://www.haircoach.net for upcoming hands-on PRP and HairCheck classes.
Looking for reviews and ratings for hair transplant surgeon Dr. Alan Bauman?
For many years, Dr. Alan J. Bauman and Bauman Medical Group has used a robust patient feedback process to continually improve patient care in hair restoration and their treatment of hair loss patients. Aside from written feedback forms and surveys, Real Patient Ratings is a google-verified HIPAA-compliant 3rd-party electronic feedback system that allows actual patients of Dr. Alan Bauman to provide feedback, complaints, concerns and reviews regarding consultations, treatments, procedures, hair transplants, PRP as well as patient care and results. Dr. Alan Bauman and his team strive daily to provide exceptional results and patient care above and beyond the accepted norms in the industry.
Visit Real Patient Ratings for authentic reviews from real patients of board certified hair restoration doctor, Dr. Alan J. Bauman of Bauman Medical Group in Boca Raton, Florida.
Approach to a case of diffuse hair loss in females
. Anagen effluvium-
(a)Dystrophic
(b)Loose anagen hair
2. Telogen effluvium –
(a)acute telogen effluvium
(b)Chronic telogen effluvium
3. Female pattern hair loss
Primary CTE –represents a primary disorder and is a diagnosis of exclusion.
Secondary CTE- secondary to variety of systemic disorders.
Iron deficiency
Other deficiency –protein calorie malnutrition ,zinc deficiency
Thyroid diseases
Metabolic diseases-chronic liver or renal failure, advanced malignancy, pancreatic disease and upper GI disorder with malabsorption
SLE and other connective tissue disorders.
HIV infection
Drug induced
Lecture by Dr. Patrick Treacy from Ailesbury Hair Clinics to ICAD 2014 Brazil on the reasons and treatments for female hair loss. Courtesy given at lecture to some other doctors and clinics for some images used. Images related to Ailesbury Hair Clinics were added at a alter time.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
For many, hair loss can be a devastating psychological condition. Unfortunately, dermatologists and primary doctors often fall short when it comes to the state-of-the-art diagnosis and treatment. It's up to hair restoration physicians and integrative practices to take the lead in the medical management of hair loss. Helping patients maintain, enhance and restore their own living and growing hair is a rewarding field to be in. Mismanaging patients expectations or therapies will certainly lead to disappointment. In this webinar, learn an overview of how we diagnose, measure, treat and track hair loss patients on various effective medical regimens. We often prescribe finasteride and FinPlus compounded finasteride, Formula82M minoxidil, LaserCap and in-office laser therapy, PRP with ECM BioD ACell, nutraceuticals and FUE NeoGraft hair transplantation. See some before and afters from various monotherapy patients. HairCheck cross sectional hair bundle trichometry is the key to keeping patients compliant. Thank you to LaserCap
Additional training is available from Dr. Alan J Bauman so visit http://www.haircoach.net for upcoming hands-on PRP and HairCheck classes.
Looking for reviews and ratings for hair transplant surgeon Dr. Alan Bauman?
For many years, Dr. Alan J. Bauman and Bauman Medical Group has used a robust patient feedback process to continually improve patient care in hair restoration and their treatment of hair loss patients. Aside from written feedback forms and surveys, Real Patient Ratings is a google-verified HIPAA-compliant 3rd-party electronic feedback system that allows actual patients of Dr. Alan Bauman to provide feedback, complaints, concerns and reviews regarding consultations, treatments, procedures, hair transplants, PRP as well as patient care and results. Dr. Alan Bauman and his team strive daily to provide exceptional results and patient care above and beyond the accepted norms in the industry.
Visit Real Patient Ratings for authentic reviews from real patients of board certified hair restoration doctor, Dr. Alan J. Bauman of Bauman Medical Group in Boca Raton, Florida.
Approach to a case of diffuse hair loss in females
. Anagen effluvium-
(a)Dystrophic
(b)Loose anagen hair
2. Telogen effluvium –
(a)acute telogen effluvium
(b)Chronic telogen effluvium
3. Female pattern hair loss
Primary CTE –represents a primary disorder and is a diagnosis of exclusion.
Secondary CTE- secondary to variety of systemic disorders.
Iron deficiency
Other deficiency –protein calorie malnutrition ,zinc deficiency
Thyroid diseases
Metabolic diseases-chronic liver or renal failure, advanced malignancy, pancreatic disease and upper GI disorder with malabsorption
SLE and other connective tissue disorders.
HIV infection
Drug induced
Lecture by Dr. Patrick Treacy from Ailesbury Hair Clinics to ICAD 2014 Brazil on the reasons and treatments for female hair loss. Courtesy given at lecture to some other doctors and clinics for some images used. Images related to Ailesbury Hair Clinics were added at a alter time.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
1. CROSS SECTION
TRICHOMETRY
UPDATE
A NEW TOOL FOR MANAGING
PATIENTS WITH HAIR LOSS
ISHRS – ANNUAL SCIENTIFIC MEETING
Nassau, Bahamas – October 18-21, 2012
Bernard Cohen, MD
Diplomate, American Board of Dermatology
Diplomate, American Board of Hair Restoration Surgery
18. HMI
(BUNDLE CROSS SECTION)
will change if or when
A full-sized hair falls out
A miniaturized hair eventually vanishes
A full-sized hair emerges from the skin
A hair diameter increases
A hair diameter decreases
22. With CST you’ll be able to answer these questions:
How quickly is untreated AGA getting worse? What percent per year?
Is it time to advance my patient from MNX to FIN?
Does FIN work as well if taken 2x per week?
Is MNX 2% bid equivalent to MNX 5% daily?
Is generic MNX equivalent to Rogaine?
Is MNX more effective with added RetinA?
Do HairMax and LaserCap work better than MNX?
Is there an added benefit of adding MNX and/or laser to FIN?
If I correct a patient’s iron deficiency, does her shedding improve?
24. Questions that CST can easily answer:
How quickly is untreated AGA getting worse? What percent per year?
Should I advance my patient from MNX to FIN?
Does FIN work as well if taken 2x per week?
Is MNX 2% bid equivalent to MNX 5% daily?
Is generic MNX equivalent to Rogaine?
Is MNX more effective with added RetinA?
Do HairMax and LaserCap work better than MNX?
Is there an added benefit of adding MNX and/or laser to FIN?
If I correct a patient’s iron deficiency, does her shedding improve?
26. Questions that CST can easily answer:
How quickly is untreated AGA getting worse? What percent per year?
Is it time to advance my patient from MNX to FIN?
Does FIN work as well if taken 2x per week?
Is MNX 2% bid equivalent to MNX 5% daily?
Is generic MNX equivalent to Rogaine?
Is MNX more effective with added RetinA?
Do HairMax and LaserCap work better than MNX?
Is there an added benefit of adding MNX and/or laser to FIN?
If I correct a patient’s iron deficiency, does her shedding improve?
27. on FINASTERIDE 1mgm daily
reduce to1mgm 2x/wk
4963 62
Theoretical example – NOT clinical observation
One year later
28. Questions that CST can easily answer:
How quickly is untreated AGA getting worse? What percent per year?
Is it time to advance my patient from MNX to FIN?
Does FIN work as well if taken 2x per week?
Is MNX 2% bid equivalent to MNX 5% daily?
Is generic MNX equivalent to Rogaine?
Is MNX more effective with added RetinA?
Do HairMax and LaserCap work better than MNX?
Is there an added benefit of adding MNX and/or laser to FIN?
If I correct a patient’s iron deficiency, does her shedding improve?
29. MNX 2% bid x 1 year
Change to MNX 5% once
daily
4975 79
MNX 5% once daily
at end of following year
Theoretical example – NOT clinical observation
30. Questions that CST can easily answer:
How quickly is untreated AGA getting worse? What percent per year?
Is it time to advance my patient from MNX to FIN?
Does FIN work as well if taken 2x per week?
Is MNX 2% bid equivalent to MNX 5% daily?
Is generic MNX equivalent to Rogaine?
Is MNX more effective with added RetinA?
Do HairMax and LaserCap work better than MNX?
Is there an added benefit of adding MNX and/or laser to FIN?
If I correct a patient’s iron deficiency, does her shedding improve?
31. MNX 5% generic
at end of year #1
Switch to Rogaine 5%
4961 62
Rogaine 5%
at end of following year
Theoretical example – NOT clinical observation
32. Questions that CST can easily answer:
How quickly is untreated AGA getting worse? What percent per year?
Is it time to advance my patient from MNX to FIN?
Does FIN work as well if taken 2x per week?
Is MNX 2% bid equivalent to MNX 5% daily?
Is generic MNX equivalent to Rogaine?
Is MNX more effective with added RetinA?
Do HairMax and LaserCap work better than MNX?
Is there an added benefit of adding MNX and/or laser to FIN?
If I correct a patient’s iron deficiency, does her shedding improve?
34. Questions that CST can easily answer:
How quickly is untreated AGA getting worse? What percent per year?
Is it time to advance my patient from MNX to FIN?
Does FIN work as well if taken 2x per week?
Is MNX 2% bid equivalent to MNX 5% daily?
Is generic MNX equivalent to Rogaine?
Is MNX more effective with added RetinA?
Do HairMax and LaserCap work better than MNX?
Is there an added benefit of adding MNX and/or laser to FIN?
If I correct a patient’s iron deficiency, does her shedding improve?
35. On MNX 5% bid x 3 years
then switch patient
to Laser Rx
4963 61
24 MONTHS LATER
Theoretical example – NOT clinical observation
36. Questions that CST can easily answer:
How quickly is untreated AGA getting worse? What percent per year?
Is it time to advance my patient from MNX to FIN?
Does FIN work as well if taken 2x per week?
Is MNX 2% bid equivalent to MNX 5% daily?
Is generic MNX equivalent to Rogaine?
Is MNX more effective with added RetinA?
Do HairMax and LaserCap work better than MNX?
Is there an added benefit of adding MNX and/or laser to FIN?
If I correct a patient’s iron deficiency, does her shedding improve?
37. FIN 1mgm daily
4957 58
FIN 1 mgm daily
plus Laser Rx
Theoretical example – NOT clinical observation
38. Questions that CST can easily answer:
How quickly is untreated AGA getting worse? What percent per year?
Is it time to advance my patient from MNX to FIN?
Does FIN work as well if taken 2x per week?
Is MNX 2% bid equivalent to MNX 5% daily?
Is generic MNX equivalent to Rogaine?
Is MNX more effective with added RetinA?
Do HairMax and LaserCap work better than MNX?
Is there an added benefit of adding MNX and/or laser to FIN?
If I correct a patient’s iron deficiency, does her shedding improve?
40. Questions that CST can easily answer:
When has the woman with telogen effluvium stabilized?
My patient is convinced that MNX has made her “worse.”
How does FUE affect donor site density?
What percent improvement does my patient have after HT surgery?
Is this woman’s hair loss caused by shedding or AGA?
.
42. Questions that CST can easily answer:
When has the woman with telogen effluvium stabilized?
My patient is convinced that MNX has made her “worse.”
How does FUE affect donor site density?
What percent improvement does my patient have after HT surgery?
Is this woman’s hair loss caused by shedding or AGA?
.
43. Baseline HMI, then
4 months of MNX.
Phone call: “I’m much worse!”
4971 71
On re-exam
the next day
she is no worse.
44. Questions that CST can easily answer:
When has the woman with telogen effluvium stabilized?
My patient is convinced that MNX has made her “worse.”
How does FUE affect donor site density?
What percent improvement does my patient have after HT surgery?
Is this woman’s hair loss caused by shedding or AGA?
.
46. Questions that CST can easily answer:
When has the woman with telogen effluvium stabilized?
My patient is convinced that MNX has made her “worse.”
How does FUE affect donor site density?
What percent improvement does my patient have after HT surgery?
Is this woman’s hair loss caused by shedding or AGA?
.
48. Questions that CST can easily answer:
When has the woman with telogen effluvium stabilized?
My patient is convinced that MNX has made her “worse.”
How does FUE affect donor site density?
What percent improvement does my patient have after HT surgery?
Is this woman’s hair loss caused by shedding or AGA?
.